Cord Blood America, Inc. (OTCBB: CBAI)

Cord Blood America, Inc. (CBAI), through its wholly owned subsidiary CorCell Companies, Inc., is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. For an initial fee of $2,075 and an annual storage fee of approx. $125 for each year thereafter, CorCell provides the following services to each customer: Collection; Full-Time Physician and Customer Support; Transportation; Comprehensive Testing; and Cord Blood Preservation. At present, all of CorCells cord blood units are tested, processed and stored at our laboratory in Las Vegas, NV.

There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. CBAI, through CorCell, markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive. Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.